275 Battery Street, 25th Floor
San Francisco, CA 94111
Join us along with the German American Business Association for an insightful seminar on the impact of targeted genome editing on medicine, healthcare and agriculture.
Progress in genome sequencing over the last 10 – 15 years has enabled genetic modification of microorganisms, crops and animals on an industrial scale to produce novel products and increase yields and production effciency. However, specific genetic engineering methods have been complicated, labor intensive, time consuming and expensive. With the discovery of CRIPSR (Clustered Regularly Interspaced Short Palindromic Repeats), gene editing has become more precise and cost effective.
Will the CRISPR excitement in science, medicine and biotechnology hold or will further testing and the start of human trials reveal challenges to the adoption of the technology? Experts will discuss mechanism, application and opportunities of CRISPR from humans to crops and touch on implications for society.
- Lynne Reuber, Ph.D., Program Director at 2 Blades Foundation
- Professor Robert David Siegel M.D., Ph.D., Teaching Professor Department of Microbiology and Immunology, Program in Human Biology, Center for African Studies, and Woods Institute for the Environment at Stanford University
- Megan Hochstrasser, Ph.D., Innovative Genomics Institute, Science Communications Manager
- Martin Kampmann, Ph.D., Assistant Professor, UCSF, Investigator, Chan Zuckerberg Biohub, Paul G. Allen Distinguished Investigator
- Peter Nell, Ph.D., VP Strategy and Business Development, Casebia
Moderator: Jun Axup, Ph.D., Scientific Director & Partner, IndieBio
Reception to follow.
6 – 6:30 p.m. Registration / Networking Reception
6:30 – 8 p.m. Program
8 – 9 p.m. Networking